Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million for proof-of-concept testing of a lead program in ...
Rapport Therapeutics announced in early January 2026 that the FDA has cleared RAP-219 to move into Phase 3 registrational trials for focal onset seizures, while the company advances a broader ...
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small ...
Rapport Therapeutics (RAPP) announced two encore poster presentations at the 2025 American Academy of Neurology, AAN, Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, ...
Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results